 | |
| Clinical data | |
|---|---|
| Trade names | Biotussin, Lomisat, Pertoxil, Silomat |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.035.373  |
| Chemical and physical data | |
| Formula | C14H22ClNO |
| Molar mass | 255.79 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Clobutinol is a cough suppressant formerly distributed by Boehringer Ingelheim and its licensees under the names Lomisat and Silomat, by Bioter as Biotussin, and by Violani-Farmavigor as Pertoxil. It has been withdrawn from the market worldwide.
Side effects include drowsiness, dizziness, insomnia, nausea, vomiting, and abdominal discomfort.[1] Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.[2] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.[3]
Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.[4]
The approval for Germany and the EU was revoked in 2008.[5]
Prior to withdrawal, it was available throughout Europe and Central America, as well as in South Africa. Trade names include Biotussin, Lomisat (Spain), Pertoxil (Italy), and in most of the world, Silomat.[6]
Clobutinol: BfArM orders cancellation of approval
Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
